The Most Cost-Effective Program the US Ever Built Is Dying. Nobody Voted to Kill It.

PEPFAR has saved 26 million lives since 2003 at a cost of roughly $1,500 to $10,000 per life. The US government spends over a thousand times that much to save a single American life in other contexts. Now eight countries are running out of HIV drugs, and the program that kept 20 million people alive is being gutted.

Nobody voted for this.

The math that should make everyone uncomfortable

George W. Bush created PEPFAR in 2003. It was reauthorized four times with bipartisan majorities. Every president since — Obama, Trump (first term), Biden — supported it. The program runs in 50+ countries and currently keeps 20 million people on antiretroviral treatment.

Its annual budget: $4.85 billion. That's less than a single Gerald R. Ford-class aircraft carrier ($13.3 billion). It's 0.07% of federal spending.

An independent team of journalists and academics at PEPFARReport.org crunched the numbers. They found the program saved between 7.5 and 30 million lives — the State Department's official figure is 26 million — at between $1,500 and $10,000 per life saved. For context, the EPA values an American statistical life at $10 million. The Department of Transportation uses $12.5 million.

PEPFAR doesn't just keep people alive. Brookings found it drives GDP growth in recipient countries, increases childhood immunizations, keeps children in school, and reduces all-cause mortality — not just HIV deaths. It prevented 5.5 million babies from being born with HIV.

By almost any measure, it's the most cost-effective thing the US government has ever done.

What's happening now

In January 2025, Trump signed a blanket executive order freezing all foreign aid for 90 days. PEPFAR wasn't the target. It was collateral damage.

The freeze halted drug shipments, shut clinics, and stopped services in more than 50 countries. A waiver was issued for "life-saving humanitarian assistance," but implementing partners found it nearly impossible to actually use. USAID — the agency that handled much of PEPFAR's logistics — was dissolved. Most staff and contractors were let go.

Then came the budget. The FY2026 request slashed PEPFAR from $4.85 billion to $2.9 billion. A 42% cut. Secretary of State Rubio called that number his goal.

The one-year Congressional reauthorization expired on March 25, 2025. Nobody renewed it. PEPFAR still exists as permanent law — it doesn't technically need reauthorization to continue — but without political will and with a gutted USAID, the program is bleeding out.

Eight countries, zero drugs

WHO Director-General Tedros Adhanom Ghebreyesus laid it out in March 2025: Nigeria, Kenya, Lesotho, South Sudan, Burkina Faso, Mali, Haiti, and Ukraine were running out of HIV drugs.

UNAIDS tracked the downstream math. A stockout in those countries, combined with disruptions across 50+ others, could produce 6.6 million new HIV infections. Around 2,300 additional new infections per day. An additional 4.2 million AIDS-related deaths — more than triple the annual death toll.

"Disruptions to HIV programmes could undo 20 years of progress," Tedros said.

In Africa, unlike the US, HIV primarily affects women and children. The people losing access to medication aren't the faces most Americans picture when they think of HIV. They're pregnant mothers whose babies will now be born with a preventable infection. They're children who were healthy last month.

The thing nobody's saying

Here's what makes this different from a policy debate about foreign aid.

PEPFAR wasn't controversial. It wasn't partisan. It wasn't wasteful. Every serious review found it worked — spectacularly. The Bush Center, hardly a liberal institution, called it the "shining jewel of US aid programs" in January 2025.

It's dying because a blanket executive order didn't carve out exceptions for things that work. Because the agency that distributed the drugs was dissolved for reasons unrelated to HIV. Because a budget proposal treated the most efficient program in government the same as the least efficient ones.

A ScienceDirect modelling study of seven sub-Saharan African countries found that even a temporary freeze results in tens of thousands of deaths. Not hypothetically. The supply chain for antiretrovirals isn't a tap you turn off and on. When clinics close, patients miss doses. When patients miss doses, the virus develops resistance. When resistance builds, you need more expensive second-line drugs. The damage compounds.

Some countries are scrambling. UNAIDS reports that governments are developing "sustainability roadmaps" and allocating emergency domestic budgets. But for countries like South Sudan and Burkina Faso, domestic funding can't fill a gap this large.

$1,500 per life

That number bears repeating. Independent analysis — not the State Department's own accounting — found PEPFAR saves lives for $1,500 to $10,000 each.

The US spent $110 billion on PEPFAR over 20 years. It saved at least 7.5 million lives, possibly 30 million. The program's cost-per-life makes it roughly a thousand times more efficient at saving human beings than almost any domestic regulatory program.

This isn't about whether the US should fund foreign aid. It's about whether the most effective thing a government has ever done deserves to die by accident.

The drugs exist. The supply chains were built. The clinics were staffed. Twenty million people were alive because of it.

Eight countries are now counting their remaining pills.